Clovis Oncology (CLVS) Posts Smaller Q2 Loss, Sales Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. ANET
6. DUOL
7. SWKS
8. XYZ
9. CVS
10. FISV

Go back to Clovis Oncology (CLVS) Posts Smaller Q2 Loss, Sales Beat

Clovis Oncology Announces Second Quarter 2017 Operating Results

August 2, 2017 4:05 PM EDT

Strong second quarter of launch for Rubraca® (rucaparib) in U.S. with $14.6M reported in net sales Positive topline data from the ARIEL3 study reported on June 19, 2017; presentation of full dataset confirmed at European Society for Medical Oncology 2017 Congress in Madrid Clovis plans to submit a supplemental New Drug Application (sNDA) for a second-line and later maintenance treatment indication before the end of October Rucaparib E.U. Marketing Authorization Application under review; establishing E.U. organization to support a potential European launch... More